Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
Digestive Remedies in France

France digestive remedies market: EUR 320 million industry in 2012


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2014-02-13 00:35:02 - Digestive Remedies in France - a new market research report on companiesandmarkets.com

Laboratoires McNeil led the France digestive remedies market in 2012, accounting for a12% share of overall value sales. Its leadership was sustained by its four key brands, Imodium, Microlax, Lansoÿl and Pepcid in laxatives, diarrhoeal remedies and H2 blockers. Laboratoires Cephalon led IBS treatments, with its brand Spasfon accounting for a 73% value share; Sanofi led antacids, the biggest value generator (32% share of overall value sales of digestive remedies), with its famous Maalox brand generating 31% of overall value sales. With the arrival of Sanofi in proton pump inhibitors in 2012 (via the launch of Ipraalox), it is highly possible that the overall leadership of Laboratoires McNeil in digestive remedies may be challenged by Sanofi by the end 2013.

The

 

 

relatively new category of proton pump inhibitors remained dynamic in 2012, with current value growth of 6%, thanks to its long term and combined curative capacity. The second generation of proton pump inhibitors (pantoprazole-based) are usually available in smaller tablets, and thus offer added convenience when compared with the bigger omeprazole tablets.

Over the forecast period, digestive remedies in France is expected to see a negative constant value CAGR of 1%. A more informed French population will continue to favour changes in eating habits and show a preference for softer medicines to alleviate digestive complications. Driven by key players and advertising campaigns, proton pump inhibitors is likely to remain the most dynamic category in digestive remedies, with a CAGR of 1% in constant value terms in the forecast period to 2017.

Key Headlines

- Digestive remedies sees a negligible current value decline in 2012, to reach €319 million
- Digestive enzymes begin to make a timid appearance in 2012, with several new launches, with the best-known being the Arko Enzym range from Laboratoires Pharmaceutiques Arkopharma
- Proton pump inhibitors records the highest current value growth of 6% in 2012
- Laboratoires McNeil leads digestive remedies with a 12% share of value sales in 2012. Nonetheless, leadership within the different categories remains fragmented
- Digestive remedies is expected to see a negative constant value CAGR of 1% over the forecast period

Click for report details: www.companiesandmarkets.com/Market/Consumer-Goods/Market-Researc ..

Browse all Consumer Goods Market Research Reports www.companiesandmarkets.com/Market/Consumer-Goods/Market-Researc ..

Browse all Consumer Goods Company Profile Reports www.companiesandmarkets.com/Market/Consumer-Goods/Company-Profil ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com